Hoth Therapeutics (NASDAQ:HOTH) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a $4.00 target price on the stock.

Several other research analysts have also recently issued reports on HOTH. Benchmark reissued a “speculative buy” rating and issued a $3.00 price objective on shares of Hoth Therapeutics in a research note on Friday, October 11th. D. Boral Capital restated a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a report on Tuesday, January 7th.

Hoth Therapeutics Stock Down 7.5 %

HOTH opened at $1.36 on Thursday. The business has a fifty day moving average of $1.05 and a 200 day moving average of $0.91. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $3.80. The stock has a market cap of $9.39 million, a P/E ratio of -1.03 and a beta of 0.75.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.01). Equities analysts anticipate that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics at the end of the most recent reporting period. Institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.